Maa: Euroopan unioni
Kieli: englanti
Lähde: EMA (European Medicines Agency)
emtricitabine, tenofovir disoproxil succinate
KRKA, d.d., Novo mesto
J05AR03
emtricitabine, tenofovir disoproxil
Antivirals for systemic use
HIV Infections
Emtricitabine/Tenofovir disoproxil Krka d.d. is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults.Emtricitabine/Tenofovir disoproxil Krka d.d. is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years.
Revision: 10
Authorised
2017-04-28
41 B. PACKAGE LEAFLET 42 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT EMTRICITABINE/TENOFOVIR DISOPROXIL KRKA D.D. 200 MG/245 MG FILM-COATED TABLETS emtricitabine/tenofovir disoproxil READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Emtricitabine/Tenofovir disoproxil Krka d.d. is and what it is used for 2. What you need to know before you take Emtricitabine/Tenofovir disoproxil Krka d.d. 3. How to take Emtricitabine/Tenofovir disoproxil Krka d.d. 4. Possible side effects 5. How to store Emtricitabine/Tenofovir disoproxil Krka d.d. 6. Contents of the pack and other information 1. WHAT EMTRICITABINE/TENOFOVIR DISOPROXIL KRKA D.D. IS AND WHAT IT IS USED FOR EMTRICITABINE/TENOFOVIR DISOPROXIL KRKA D.D. CONTAINS TWO ACTIVE SUBSTANCES, _emtricitabine _and _tenofovir disoproxil_. Both of these active substances are _antiretroviral _medicines which are used to treat HIV infection. Emtricitabine is a _nucleoside reverse transcriptase inhibitor _and tenofovir is a _nucleotide reverse transcriptase inhibitor. _However, both are generally known as NRTIs and they work by interfering with the normal working of an enzyme (reverse transcriptase) that is essential for the virus to reproduce itself. - EMTRICITABINE/TENOFOVIR DISOPROXIL KRKA D.D. IS USED TO TREAT HUMAN IMMUNODEFICIENCY VIRUS 1 (HIV-1) INFECTION IN ADULTS. - IT IS ALSO USED TO TREAT HIV IN ADOLESCENTS AGED 12 TO LESS THAN 18 YEARS WHO WEIGH AT LEAST 35 KG, and who have already been treated with other HIV medicines that are no longer effective or hav Lue koko asiakirja
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Emtricitabine/Tenofovir disoproxil Krka d.d. 200 mg/245 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 200 mg of emtricitabine and 245 mg of tenofovir disoproxil (equivalent to 300.7 mg of tenofovir disoproxil succinate or 136 mg of tenofovir). Excipient(s) with known effect Each film-coated tablet contains 80 mg lactose monohydrate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet). Emtricitabine/Tenofovir disoproxil Krka d.d. film-coated tablets are blue, oval, biconvex tablets, of dimensions 20 mm x 10 mm. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Emtricitabine/Tenofovir disoproxil Krka d.d. is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults (see section 5.1). Emtricitabine/Tenofovir disoproxil Krka d.d. is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents (see section 4.2, 4.4 and 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Emtricitabine/Tenofovir disoproxil Krka d.d. should be initiated by a physician experienced in the management of HIV infection. Posology _Adults and adolescents aged 12 years and older, weighing at least 35 kg:_ One tablet, once daily. Separate preparations of emtricitabine and tenofovir disoproxil are available for treatment of HIV-1 infection if it becomes necessary to discontinue or modify the dose of one of the components of Emtricitabine/Tenofovir disoproxil Krka d.d.. Please refer to the Summary of Product Characteristics for these medicinal products. If a dose of Emtricitabine/Tenofovir disoproxil Krka d.d. is missed within 12 hours of the time it is usually taken, Emtricitabine/Tenofovir disoproxil Krka d.d. should be taken as soon as possible and the normal dosing schedule should be resumed. If a dose of Emtricitabine/Tenofovir disoproxil Krka d.d. is misse Lue koko asiakirja